Paul Hastings advised Piper Sandler and Co. and Oppenheimer & Co. in connection with Skye Bioscence, Inc.’s PIPE

Paul Hastings LLP advised Piper Sandler and Co. as lead placement agent, and Oppenheimer & Co. as placement agent in connection with Skye Bioscence, Inc.’s  private placement (PIPE). The PIPE consists of the sale of 4,000,000 shares of common stock at $10.00 per share to certain investors. Skye, Inc., (OTCQB: SKYE) is a clinical stage biotechnology company focused on discovering, developing and commercializing novel classes of therapeutic drugs that modulate the endocannabinoid system.

Partner and Co-head of Equity Capital Markets and Co-chair of the Corporate Life Sciences Group Seo Salimi, and Securities and Capital Markets partner Will Magioncalda led the Paul Hastings team, which included associate Chris Guerin.

More details can be found here. 

About Paul Hastings

With widely recognized elite teams in finance, mergers & acquisitions, private equity, restructuring and special situations, litigation, employment, and real estate, Paul Hastings is a premier law firm providing intellectual capital and superior execution globally to the world’s leading investment banks, asset managers, and corporations.